Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
crawled date : 2022 - 07 - 28 source : Www.biospace.com save search
Sanofi Launches HBCU Diversity Partnership, Stays Strong in Q2 as Dupixent Th...
Published: 2022-07-28 (Crawled : 18:00) - biospace.com/
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 0.4%
H: 1.01%
C: 0.17%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.68%
H: 0.0%
C: 0.0%
dupixent sanofi
Sanofi Launches HBCU Diversity Partnership, Stays Strong in Q2 as Dupixent Thrives
Published: 2022-07-28 (Crawled : 18:00) - biospace.com/
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 0.4%
H: 1.01%
C: 0.17%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.68%
H: 0.0%
C: 0.0%
dupixent sanofi
Kiora Pharmaceuticals Issued US Patent Covering KIO-201 Technology in Combination with Antibiotics
Published: 2022-07-28 (Crawled : 17:00) - biospace.com/
KPRX | $0.504 -13.03% -14.98% 290K
|
Manufacturing
|
| O: 0.34%
H: 3.38%
C: 0.47%
kio-201 antibiotics patent technology
Sanofi Stays Strong in Q2 as Dupixent thrives. Launches HBCU Diversity Partnership
Published: 2022-07-28 (Crawled : 16:00) - biospace.com/
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 0.4%
H: 1.01%
C: 0.17%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.68%
H: 0.0%
C: 0.0%
partnership dupixent sanofi
Acer Therapeutics and Relief Therapeutics Announce FDA Acceptance for Review of NDA Resubmission for ACER-001 for Treatment of UCDsPrescription Drug User Fee Act (PDUFA) target action date set for January 15, 2023
Published: 2022-07-28 (Crawled : 15:20) - biospace.com/
RLFTF | $1.45 11.45% 1.3K
|
n/a
|
| O: 3.08%
H: 0.0%
C: -6.79%
ACER | $0.9 -3.61% 420K
|
Health Technology
|
| O: 0.7%
H: 4.86%
C: -1.39%
acer-001 treatment fda drug set resubmission therapeutics review
Synlogic Announces Second Quarter 2022 Conference Call and Webcast
Published: 2022-07-28 (Crawled : 15:20) - biospace.com/
SYBX | $1.9 -0.52% -0.53% 19K
|
Health Technology
|
| O: 2.91%
H: 0.0%
C: -10.2%
conference
GigaGen Publishes Research Showcasing First-Ever Clinical GMP Manufacturing and IND-Enabling Studies for its New Class of Drugs, Recombinant Polyclonal Antibodies
Published: 2022-07-28 (Crawled : 15:20) - biospace.com/
GRFS | $6.4 -1.23% -1.25% 960K
|
Health Technology
|
| O: -10.0%
H: 4.69%
C: -0.21%
research
Sanofi Stays Strong in Q2 as Dupixent thrives. Launches HBCU Diversity Partne...
Published: 2022-07-28 (Crawled : 15:20) - biospace.com/
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 0.4%
H: 1.01%
C: 0.17%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.68%
H: 0.0%
C: 0.0%
dupixent sanofi
Propanc Biopharma’s CSO Reflects on Unique Anti-Cancer Effects of PRP Discovered Over Past Decade
Published: 2022-07-28 (Crawled : 15:00) - biospace.com/
PPCB | $0.0011 -41.86% 5.6M
|
Manufacturing
|
| O: 2.38%
H: 0.0%
C: -18.6%
unique cancer
BIO-TECHNE ANNOUNCES LICENSING AGREEMENT AND PARTNERSHIP WITH UNIVERSITY OF DUNDEE
Published: 2022-07-28 (Crawled : 15:00) - biospace.com/
TECH | $63.48 -0.33% -0.33% 980K
|
Health Technology
|
| O: 0.57%
H: 2.03%
C: 1.12%
partnership agreement
Sareum submits Clinical Trial Authorisation application to UK MHRA for development of TYK2/JAK1 inhibitor SDC-1801 and provides an Operational Update
Published: 2022-07-28 (Crawled : 15:00) - biospace.com/
GLAXF | News | $19.54 -14.18% 2.6K
|
Health Technology
|
| O: -1.01%
H: 0.0%
C: -2.13%
GSK | News | $40.86 -0.92% -0.15% 1.7M
|
Health Technology
|
| O: -1.54%
H: 0.91%
C: 0.14%
sdc-1801 application trial update
ViiV Healthcare Announces New Data at AIDS 2022 From Unblinded Phase of HPTN 084 Study in Women in Sub-Saharan Africa Showing Continued Superior Efficacy of Injectable Cabotegravir Long-Acting for PrEP Over Daily, Oral TDF/FTC Tablets
Published: 2022-07-28 (Crawled : 15:00) - biospace.com/
PFE | News 4 | $26.27 -0.19% -0.15% 23M
|
Health Technology
|
| O: -2.13%
H: 2.92%
C: -0.25%
women study africa
ViiV Healthcare and the Medicines Patent Pool Sign New Voluntary Licensing Agreement to Expand Access to Innovative Long-Acting HIV Prevention Medicine
Published: 2022-07-28 (Crawled : 15:00) - biospace.com/
PFE | News 4 | $26.27 -0.19% -0.15% 23M
|
Health Technology
|
| O: -2.13%
H: 2.92%
C: -0.25%
patent hiv agreement
Tonix Pharmaceuticals Announces Collaboration with Kenya Medical Research Institute to Develop TNX-801 in Kenya as a Vaccine for the Prevention of Monkeypox and Smallpox Infection
Published: 2022-07-28 (Crawled : 15:00) - biospace.com/
TNXP | $0.1587 1.21% 1.2% 950K
|
Health Technology
|
| O: 5.62%
H: 11.83%
C: 10.65%
tnx-801 monkeypox smallpox research collaboration vaccine infection
Sientra to Report Second Quarter 2022 Financial Results on August 11, 2022
Published: 2022-07-28 (Crawled : 15:00) - biospace.com/
SIEN | $0.174 0.69% 3.4M
|
Health Technology
|
| O: 0.54%
H: 5.46%
C: 1.46%
report results
Clarus Therapeutics Announces Notice of Allowance for Additional Patent Claims Covering JATENZO® (testosterone undecanoate)
Published: 2022-07-28 (Crawled : 15:00) - biospace.com/
CRXT | $0.0475
|
|
| O: 4.29%
H: 1.99%
C: -3.73%
jatenzo patent therapeutics
The New England Journal of Medicine Publishes Positive Phase 2 Data on Litifilimab (BIIB059) in Cutaneous Lupus Erythematosus
Published: 2022-07-28 (Crawled : 15:00) - biospace.com/
BIIB | $201.91 4.52% 4.32% 3.3M
|
Health Technology
|
| O: -0.26%
H: 1.35%
C: 0.87%
biib059 lupus positive phase 2
Algernon Pharmaceuticals Reports Additional Positive Data From its Phase 2 Study of Ifenprodil for IPF and Chronic Cough
Published: 2022-07-28 (Crawled : 15:00) - biospace.com/
AGNPF | $0.089 178.69% 75K
|
Health Technology
|
| O: 0.12%
H: 1.62%
C: 1.62%
positive study phase 2
FDA Clears DyAnsys Neurostimulation Device Primary Relief to Treat C-Section Pain
Published: 2022-07-28 (Crawled : 14:20) - biospace.com/
ANSS | $328.65 0.82% 0.82% 220K
|
Technology Services
|
| O: -0.26%
H: 4.84%
C: 4.52%
fda device
Tallac Therapeutics Announces First Patient Dosed with TAC-001, a First-in-Class Toll-like Receptor 9 Agonist Antibody Conjugate, in a Phase 1/2 Study for Patients with Advanced Solid Tumors
Published: 2022-07-28 (Crawled : 14:20) - biospace.com/
ALXO M | $16.24 4.77% 4.56% 440K
|
Commercial Services
|
| O: -0.33%
H: 0.25%
C: -7.46%
tac-001 antibody therapeutics study
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.